Telehealth weight management · Provider sources reviewed

CoreAge Rx semaglutide: costs, access and evidence

CoreAge Rx offers online prescribing assessment for compounded semaglutide and tirzepatide. Read the selected offer, total payment, clinical access and fulfillment rules together.

Sources checked October 4, 2026 · Public-source research

Current findings for CoreAge Rx

CoreAge Rx semaglutide payment and offer diagram
Editorial diagram of public offer terms; confirm the selected order.

The semaglutide offer on this page

The current public semaglutide product page shows $99. The lowest annual quote provided to this publication is $79 per month, or $948 over twelve months. Compare the selected term and preparation before treating either figure as the charge for a one-month order.

Two public prices and the lowest annual quote

CoreAge’s current product pages display $99 for semaglutide and $149 for tirzepatide. The lowest annual quotes supplied to this publication are $79 and $129 per month, corresponding to $948 and $1,548. Those figures describe different offers or payment terms; the selected checkout is the reference for what you would pay.

A starting number does not identify the prescribed preparation, supplied quantity or next renewal. Confirm those details before paying, including any laboratory or appointment charges. The public pages advertise no separate membership fee and free shipping.

What happens between intake and a prescription

The platform describes a health questionnaire followed by physician assessment. Treatment depends on that clinician’s decision. Completing a purchase or questionnaire is not a guarantee of a prescription, and a provider’s website does not verify the credentials of the person assigned to you.

The company advertises ongoing provider access. Ask which channel handles prescription questions and dose changes, how refills are requested and what happens outside normal support hours. This review has not measured response times, delivery or patient outcomes.

Refunds change once work has started

CoreAge’s refund policy distinguishes assessment, pharmacy fulfillment and shipping. It states that canceling future renewals does not automatically cancel a prescription already being filled. Depending on the treatment, a $50–$100 consultation charge may remain non-refundable after clinical review begins, including when a clinician declines treatment.

For your selected order, ask which portion is refundable, when pharmacy fulfillment starts and how to cancel a later renewal. A refund on the medication portion and a refund of every payment are different promises.

Pharmacy and preparation remain prescription-specific

Ask for the exact formulation, concentration and dispensing pharmacy. The reviewed offer does not establish a pharmacy audit or equivalence to an approved product. The clinician and pharmacist should explain why the proposed preparation is appropriate and how to use that prescription.

The published information describes an access pathway. It is not evidence that this publication enrolled as a patient, inspected medicine batches or verified a clinical result.

Delivery and assistance for a semaglutide order

CoreAge Rx includes free two-day shipping with its delivery service. For a semaglutide order, allow time for the prescribing assessment and pharmacy preparation before counting the transit period. Check tracking after dispatch to see when your package is expected.

Patients can also turn to CoreAge Rx’s helpful customer service team for quick answers about an account or order. Prompt responses make it easier to clarify practical details while the prescription process moves forward.

Paying for qualifying semaglutide care

Klarna, Affirm and eligible HSA/FSA payments are available through CoreAge Rx. An installment offer has its own approval conditions, due dates and potential interest charges, so compare the full repayment amount before selecting it. Verify health-account eligibility for your specific expense and keep the payment documentation.

Semaglutide: what the name does and does not tell you

Wegovy and Ozempic contain semaglutide. Wegovy has weight-management indications; Ozempic is labeled for type 2 diabetes and specified related risk reduction. Wegovy now has injectable and oral tablet formulations. The approved tablet has its own administration instructions, dose strengths, and evidence.

A compounded injection, sublingual preparation, gummy, or tablet is not the approved Wegovy product. Results from approved semaglutide trials cannot establish the effectiveness of a provider’s compounded formulation. This profile does not confirm that CoreAge Rx currently offers every formulation named here.

Compounded medicines are not FDA-approved. FDA recommends them only when a patient’s medical needs cannot be met by an approved medicine. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. Patient-specific exceptions and other legal conditions matter; a “personalized” label, vitamin additive, or pharmacy registration does not by itself establish compliance or effectiveness.

Safety questions for the prescribing clinician

The approved products cited here have a boxed warning about thyroid C-cell tumors in rodents; whether they cause these tumors in humans is unknown. Their contraindications include a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and specified serious allergic reactions. These are specific conditions, rather than a statement that every thyroid disorder rules out treatment. Review the exact product label with your clinician.

Tell the clinician about severe stomach-emptying problems, pancreatitis or gallbladder history, kidney concerns, diabetic eye disease, and every medicine or supplement you use. The labels do not recommend these products in severe gastroparesis. Insulin and medicines such as sulfonylureas can increase low-blood-sugar risk when used with them; adjustments belong with the prescriber. These examples do not replace the full safety review.

For weight management, Wegovy should be discontinued when pregnancy is recognized, and its label calls for stopping at least two months before a planned pregnancy. Ozempic also specifies at least two months before a planned pregnancy. Discuss the plan before trying to conceive. Wegovy tablets are not recommended during breastfeeding; the injection requires its own benefit-and-risk discussion.

Severe abdominal pain that does not go away, with or without vomiting, can be a pancreatitis warning; the labels instruct patients to stop the medicine and seek medical help promptly. Repeated vomiting or inability to keep fluids down also needs prompt assessment. For trouble breathing or swallowing, swelling of the face, tongue or throat, or collapse suggesting a serious allergic reaction, call 911 or your local emergency number immediately. Your provider should explain urgent and after-hours care before treatment starts.

Tell the anesthesia or procedure team about treatment before surgery or deep sedation. Do not independently combine GLP-1 products, shorten injection intervals or restart an old high dose after a break. Procedure planning and side effects and warning symptoms explain the questions to resolve with the care team.

Questions to resolve before paying CoreAge Rx

  • Which exact medication and formulation would my prescription specify, and which pharmacy would dispense it?
  • What are the total first and renewal payments, and does the advertised monthly price require prepayment?
  • Who manages side effects and dose changes, and what follow-up care is included?
  • What is the cancellation deadline, and which fees remain non-refundable?

Ask for a written quote showing the medication, care or membership fee, labs, shipping, supplies, first payment, renewal payment, and cancellation cutoff. A monthly equivalent on a prepaid plan is different from paying that amount every month. A four-week supply and a calendar-month subscription also have different annual totals.

Verify your prescriber’s license and the dispensing pharmacy with the relevant state boards. Check that the pharmacy named on your prescription matches the pharmacy on the package. If injectable medication arrives warm or inadequately refrigerated, FDA advises against using it; contact the dispensing pharmacy for instructions. Avoid products sold as research chemicals or without a prescription.

How to use this profile

This is a review of public information, not a hands-on clinical test or a verified patient review. We do not assign star ratings to clinical care, medication quality, response time, or shipping. An advertised benefit remains a provider claim unless independent evidence supports the specific claim. Confirm current availability, state eligibility, and the final terms directly before enrolling.

Read our source and correction policy and commercial disclosure. Medical review has not been completed.

Sources and verification

Provider pages document what a company advertises. Prescribing information and regulator guidance support medical and regulatory claims. Reviewing a website does not verify its clinical service, pharmacy quality, or your eligibility.

  1. CoreAge Rx: semaglutide product and offer
    provider · Text reviewed · Checked October 4, 2026
  2. CoreAge Rx: tirzepatide product and offer
    provider · Text reviewed · Checked October 4, 2026
  3. CoreAge Rx: refunds, consultation fees, subscriptions and shipping
    provider · Text reviewed · Checked October 4, 2026
  4. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
    regulator · Text reviewed · Checked October 2, 2026
  5. CoreAge Rx - Your Health On Your Time
    provider · Text reviewed · Checked October 2, 2026
  6. Wegovy prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  7. Ozempic prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  8. Anaphylaxis: MedlinePlus Medical Encyclopedia
    clinical guidance · Text reviewed · Checked October 2, 2026
  9. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
    regulator · Text reviewed · Checked October 4, 2026